iTeos Therapeutics, Inc. (NASDAQ:ITOS) Sees Significant Decrease in Short Interest

iTeos Therapeutics, Inc. (NASDAQ:ITOS) saw a significant decrease in short interest in February. As of February 28th, there was short interest totalling 1,280,000 shares, a decrease of 19.0% from the February 13th total of 1,580,000 shares. Based on an average daily trading volume, of 362,400 shares, the short-interest ratio is presently 3.5 days. Approximately 3.9% of the shares of the stock are sold short.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. GSA Capital Partners LLP bought a new position in iTeos Therapeutics in the 3rd quarter valued at $263,000. Empowered Funds LLC raised its position in iTeos Therapeutics by 5.4% in the 3rd quarter. Empowered Funds LLC now owns 65,767 shares of the company’s stock worth $671,000 after purchasing an additional 3,350 shares during the period. Quest Partners LLC increased its position in shares of iTeos Therapeutics by 914.7% in the third quarter. Quest Partners LLC now owns 11,020 shares of the company’s stock valued at $113,000 after acquiring an additional 9,934 shares during the period. Intech Investment Management LLC purchased a new position in shares of iTeos Therapeutics in the third quarter valued at about $154,000. Finally, Massachusetts Financial Services Co. MA bought a new stake in shares of iTeos Therapeutics during the 3rd quarter valued at about $242,000. 97.16% of the stock is owned by institutional investors.

iTeos Therapeutics Stock Down 1.8 %

ITOS traded down $0.13 on Wednesday, hitting $6.96. The company’s stock had a trading volume of 236,984 shares, compared to its average volume of 456,518. The company’s 50 day simple moving average is $7.44 and its 200-day simple moving average is $8.87. The firm has a market cap of $265.83 million, a P/E ratio of -2.21 and a beta of 1.38. iTeos Therapeutics has a 12 month low of $6.67 and a 12 month high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last released its quarterly earnings data on Wednesday, March 5th. The company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.14) by $0.13. Equities analysts predict that iTeos Therapeutics will post -3.49 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Wells Fargo & Company reduced their price objective on shares of iTeos Therapeutics from $19.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, March 6th. Wedbush reissued an “outperform” rating and set a $25.00 price objective on shares of iTeos Therapeutics in a research report on Wednesday, March 5th. JPMorgan Chase & Co. cut their price objective on shares of iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating on the stock in a research report on Thursday, March 6th. Finally, HC Wainwright reissued a “buy” rating and set a $46.00 price objective on shares of iTeos Therapeutics in a research report on Thursday, March 6th.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.